Search results for "maintenance"

showing 10 items of 392 documents

Oligodendrocytes support axonal transport and maintenance via exosome secretion

2020

Neurons extend long axons that require maintenance and are susceptible to degeneration. Long-term integrity of axons depends on intrinsic mechanisms including axonal transport and extrinsic support from adjacent glial cells. The mechanisms of support provided by myelinating oligodendrocytes to underlying axons are only partly understood. Oligodendrocytes release extracellular vesicles (EVs) with properties of exosomes, which upon delivery to neurons improve neuronal viability in vitro. Here, we show that oligodendroglial exosome secretion is impaired in 2 mouse mutants exhibiting secondary axonal degeneration due to oligodendrocyte-specific gene defects. Wild-type oligodendroglial exosomes …

0301 basic medicineMaleMutantHippocampusCentrifugationExosomesAxonal TransportHippocampusMass SpectrometryAnalytical ChemistryMiceMyelin0302 clinical medicineNerve FibersSpectrum Analysis TechniquesAnimal CellsMedicine and Health SciencesBiology (General)Myelin SheathNeuronsLiquid ChromatographyGeneral NeuroscienceChromatographic TechniquesBrainCell biologyChemistrySeparation ProcessesOligodendrogliamedicine.anatomical_structureCell ProcessesPhysical SciencesFemaleCellular TypesCellular Structures and OrganellesAnatomyGeneral Agricultural and Biological SciencesNeurogliaResearch ArticleSignal TransductionMaintenanceQH301-705.5Liquid Chromatography-Mass SpectrometryBiologyResearch and Analysis MethodsExosomeGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesExtracellular VesiclesmedicineAnimalsHumansSecretionVesiclesGeneral Immunology and MicrobiologyWild typeBiology and Life SciencesCell BiologyIn vitroAxonsMicrovesiclesMice Inbred C57BL030104 developmental biologyHEK293 Cellsnervous systemCellular NeuroscienceAxoplasmic transportNeuronUltracentrifugation030217 neurology & neurosurgeryNeuroscience
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct

Functional analysis of TLK2 variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their p…

2020

IntroductionThe Tousled-like kinases 1 and 2 (TLK1 and TLK2) are involved in many fundamental processes, including DNA replication, cell cycle checkpoint recovery and chromatin remodelling. Mutations in TLK2 were recently associated with ‘Mental Retardation Autosomal Dominant 57’ (MRD57, MIM# 618050), a neurodevelopmental disorder characterised by a highly variable phenotype, including mild-to-moderate intellectual disability, behavioural abnormalities, facial dysmorphisms, microcephaly, epilepsy and skeletal anomalies.MethodsWe re-evaluate whole exome sequencing and array-CGH data from a large cohort of patients affected by neurodevelopmental disorders. Using spatial proteomics (BioID) and…

0301 basic medicineNeurobiologia del desenvolupamentMicrocephalymissenseMolecular biologyBiologymedicine.disease_causemedicalloss of function mutation03 medical and health sciencesmutation.0302 clinical medicineNeurodevelopmental disordermedicineChromatin maintenanceMissense mutationmolecular biologygeneticsDevelopmental neurobiologyKinase activitygenetic research; genetics; loss of function mutation; medical; missense; molecular biology; mutationGenetics (clinical)Exome sequencingBiologia molecularGeneticsMutationgenetic researchmedicine.diseaseChromatin030104 developmental biologymutationgenetic030217 neurology & neurosurgery
researchProduct

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.

2018

Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe the design of JAVELIN Gastric 100 (NCT02625610), an open-label, Phase III trial. A total of 499 patients with locally advanced/metastatic HER2- gastric/gastroesophageal junction cancer adenocarcinoma, who had achieved at least stable disease following 12 weeks of first-line oxaliplatin/fluoropyrimidine chemotherapy, have been randomized 1:1 to receive avelumab maintenance therapy or continue chemotherapy. The primary objective is to demonstrate superior…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabmedicine.medical_treatmentAntineoplastic AgentsAntibodies Monoclonal HumanizedMaintenance ChemotherapyAvelumab03 medical and health sciences0302 clinical medicineMaintenance therapyStomach NeoplasmsInternal medicineBiomarkers TumorMedicineHumansMolecular Targeted TherapyNeoplasm StagingChemotherapybusiness.industryCancerAntibodies MonoclonalGeneral Medicinemedicine.diseaseOxaliplatin030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisMonoclonalAdenocarcinomabusinessmedicine.drugFuture oncology (London, England)
researchProduct

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advance…

2016

TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryLocally advancedbiology.organism_classificationAvelumab03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyMaintenance therapyJavelin030220 oncology & carcinogenesisInternal medicinemedicineIn patientFirst line chemotherapyReceptorbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis

2018

Abstract Introduction Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation. In this scenario a new class of drugs, the PARP inhibitors (PARPis), produced a significant improvement in long-term disease control. In order to make an aggregate evaluation of the impact of these agents, we performed a systematic review and meta-analysis. Patients and Methods Clinical trials were selected by searching “Pubmed” database and abstracts from major cancer meetings. We considered the January 2008 - April 2018 time frame. Progression free surv…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorslaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawOvarian cancerInternal medicinemedicineHumansMeta-analysiProgression-free survivalAdverse effectOvarian Neoplasmsbusiness.industryHazard ratioHematologyPrognosisClinical trial030104 developmental biologyPARP inhibitorOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCohortFemaleRandomized clinical trialMaintenance therapybusiness
researchProduct

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

2017

International audience; T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatm…

0301 basic medicinePediatricsmedicine.medical_specialtymedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/CancerPrecursor T-Cell Lymphoblastic Leukemia-LymphomachemotherapyGeneral Biochemistry Genetics and Molecular Biology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences[ MATH.MATH-AP ] Mathematics [math]/Analysis of PDEs [math.AP][SDV.CAN] Life Sciences [q-bio]/CancerMaintenance therapythymusT-cell lymphoblastic lymphomamedicineHumanscancer[MATH.MATH-AP]Mathematics [math]/Analysis of PDEs [math.AP]Computer Simulationmathematical modelling[MATH.MATH-AP] Mathematics [math]/Analysis of PDEs [math.AP]educationrandomized controlled clinical trialGeneral Environmental SciencePharmacologyChemotherapyeducation.field_of_studyGeneral Immunology and Microbiologybusiness.industryApplied MathematicsGeneral NeuroscienceLymphoblastic lymphomaCancerGeneral MedicineModels Theoreticalmedicine.disease3. Good healthLymphomaSurgeryClinical trial030104 developmental biologyModeling and SimulationCohortDisease ProgressionbusinessMathematical Medicine and Biology
researchProduct

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

2019

Abstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates. Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &lt…

0301 basic medicinePediatricsvancomycininfusion procedures0302 clinical medicinenewbornMedicinePharmacology (medical)Randomized Controlled Trials as Topiceducation.field_of_studyMaintenance doseAnti-Bacterial Agents3. Good healthInfectious Diseasesdrug maintenance doseResearch DesignArea Under CurveData Interpretation Statisticalcreatinine testsVancomycinMonte Carlo Methodmedicine.drugMicrobiology (medical)medicine.medical_specialty030106 microbiologyPopulationGestational AgeMicrobial Sensitivity TestsLoading doseRS03 medical and health sciencesPharmacokineticsdrug loading dose030225 pediatricsHumanssteady stateeducationPharmacologyDose-Response Relationship Drugbusiness.industryBody WeightInfant NewbornPostmenstrual AgeinfantNONMEMRegimen[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieregimen[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessserum
researchProduct

Dextransucrase Expression Is Concomitant with that of Replication and Maintenance Functions of the pMN1 Plasmid in Lactobacillus sakei MN1

2017

The exopolysaccharide synthesized by Lactobacillus sakei MN1 is a dextran with antiviral and immunomodulatory properties of potential utility in aquaculture. In this work we have investigated the genetic basis of dextran production by this bacterium. Southern blot hybridization experiments demonstrated the plasmidic location of the dsrLS gene, which encodes the dextransucrase involved in dextran synthesis. DNA sequencing of the 11,126 kbp plasmid (pMN1) revealed that it belongs to a family which replicates by the theta mechanism, whose prototype is pUCL287. The plasmid comprises the origin of replication, repA, repB, and dsrLS genes, as well as seven open reading frames of uncharacterized f…

0301 basic medicinePlasmid preparationMicrobiology (medical)ProbioticsLactobacillus sakeilcsh:QR1-502Biologybiology.organism_classificationOrigin of replicationMolecular biologyMicrobiologyPlasmidlcsh:MicrobiologyLactobacillus sakeiPlasmid maintenanceDextransucrase03 medical and health sciences030104 developmental biologyPlasmidGene expressionLactic acid bacteriaDextransucraseGeneDextran
researchProduct

Sox8 and Sox10 jointly maintain myelin gene expression in oligodendrocytes

2017

In Schwann cells of the vertebrate peripheral nervous system, induction of myelination and myelin maintenance both depend on the HMG-domain-containing transcription factor Sox10. In oligodendrocytes of the central nervous system, Sox10 is also essential for the induction of myelination. Its role in late phases of myelination and myelin maintenance has not been studied so far. Here, we show that these processes are largely unaffected in mice that lack Sox10 in mature oligodendrocytes. As Sox10 is co-expressed with the related Sox8, we also analyzed oligodendrocytes and myelination in Sox8-deficient mice. Again, we could not detect any major abnormalities. Expression of many myelin genes was …

0301 basic medicineSOX10Central nervous systemGene ExpressionBiologyMice03 medical and health sciencesCellular and Molecular NeuroscienceMyelin0302 clinical medicineGene expressionmedicineAnimalsHumansCell LineageGeneMyelin SheathMice KnockoutSOXE Transcription FactorsHEK 293 cellsOligodendrocyteOligodendrogliaHEK293 Cells030104 developmental biologymedicine.anatomical_structurenervous systemNeurologyMyelin maintenanceembryonic structuresSchwann CellsNeuroscience030217 neurology & neurosurgeryHeLa CellsGlia
researchProduct